A set of reports highlighted incremental but operationally important improvements to care delivery and monitoring. In women’s health, Aspira Women’s Health inked a deal with Cleveland Clinic to expand access to patient samples and accelerate multiomic diagnostic development. Separately, new clinical decision support for chronic infections and sepsis risk modeling points to a broader shift toward workflow-integrated diagnostics rather than standalone testing. Together, the items reflect how biotech-adjacent platforms—biomarker discovery and EHR-embedded monitoring—are increasingly aimed at measurable process outcomes.